TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Pfizer Halts Heart Failure Drug Trial Early on Good News Derek Lowe submits: Pfizer (PFE) was able to announce some good news today - their trial of Inspra (eplerenone) for patients with a particular combination of heart failure symptoms. The trial was halted early, but (for once) because the endpoints were reached so early that it would have been unethical to continue the placebo arm. It's always nice to hear about one of those; we don't get them that often. The drug is an aldosterone antagonist which had already been approved several years ago for heart failure and hypertension, so it's not really a surprise that it worked in this population. But you never know, and Pfizer wanted to be able to get specifically recommended for patients of this type. And that they will.Complete Story » seekingalpha.com |
Onyx Was Right to Acquire Proteolix All Along Prohost Biotech submits:In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the-art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer. Carfilzomib is the second proteasome inhibitor; these drugs work by interrupting a key enzyme cancer cells require to survive and multiply. Velcade, developed by Millennium Pharmaceuticals that was acquired by Takeda, was the first proteasome inhibitor approved. Carfilzomib was developed to be more potent than Velcade and cause milder side effects, particularly the numbness and nerve pain that are well-known issues with Velcade. Complete Story » seekingalpha.com |
NexMed, Inc. Q2 2010 Earnings Call Transcript NexMed, Inc. (NEXM)Q2 2010 Earnings CallAugust 13, 2010, 12:00 PM ETComplete Story » seekingalpha.com |
Live Like a Champion Tour - Video The 2010 Anthem Blue Cross Live Like a Champion Tour Celebrates its Fifth Annual Youth Fitness Program in Partnership with the California Governor's Council on Physical Fitness and Sports feedproxy.google.com |
Neurocrine Biosciences Seen Running Out of Gas optionMONSTER submits: By David Russell Neurocrine Biosciences (NBIX) has made a big move, and now the bulls are throwing in the towel.Complete Story » seekingalpha.com |